Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma

Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020-07, Vol.15 (7), p.e0236159-e0236159
Main Authors: Gunerka, Paweł, Gala, Kamila, Banach, Martyna, Dominowski, Jakub, Hucz-Kalitowska, Joanna, Mulewski, Krzysztof, Hajnal, Agnes, Mikus, Endre G., Smuga, Damian, Zagozda, Marcin, Dubiel, Krzysztof, Pieczykolan, Jerzy, Zygmunt, Beata M., Wieczorek, Maciej
Format: Article
Language:English
Subjects:
Allergens
Allergies
Antigens
Asthma
Biology and Life Sciences
Cytokines
Drugs
Inflammatory diseases
Inhalation
Inhibitors
Lung diseases
Lungs
Medicine and Health Sciences
R&D
Research & development
Respiration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended to be a preclinical candidate for dry powder inhalation in asthma treatment. Studies we performed showed that this molecule is safe and effective PI3Kδ inhibitor that can impact many immune functions. We developed a short, 15-day HDM induced asthma mouse model, in which we showed that CPL302-253 is able to block inflammatory processes leading to asthma development in vivo.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0236159